GLP-1 receptor agonist medications are FDA-approved for adults who meet one of the following criteria: a body mass index (BMI) of 30 or higher (classified as obesity), or a BMI of 27 or higher (overweight) combined with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease
Yang et al described the damaging effects of TMAO on pancreatic acinar cells
This amount is lower than the dose used in animal experiments after conversion [13,32,33]
Managing stress through structured physical activity, consistent routines, and intentional recovery is not a soft lifestyle recommendation
Coverage, however, varies widely by plan and employer, and many insurers still place restrictions on coverage for weightloss medications